[EN] TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES DE TRANS PYRROLIDINYLE ET LEUR UTILISATION PHARMACEUTIQUE
申请人:FAUST PHARMACEUTICALS
公开号:WO2005118533A1
公开(公告)日:2005-12-15
The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II) in which: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(-R11)m group wherein R10 is -CO-, -CS-, -O-, -S-, -SO-, -SO2-, -COO-, -CONRa-, -N(Ra)CO-, -CSNRa-, -N(Ra)CS-, -N(Ra)-, Rb, aryl, and R11 is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.
本发明涉及使用式(I)或(II)的trans吡咯烷基,其中:R1、R2或R3是氢或羧基或氨基保护基;R4至R8代表氢或烷基基团;R9代表(R10)n(-R11)m基团,其中R10是-CO-、-CS-、-O-、-S-、-SO-、-SO2-、-COO-、-CONRa-、-N(Ra)CO-、-CSNRa-、-N(Ra)CS-、-N(Ra)-、Rb、芳基,R11是一个极性基团,用于治疗和/或预防与改变谷氨酸能信号和/或功能有关的疾病,以及可以通过改变哺乳动物体内谷氨酸水平或信号传导而受影响的疾病。